Journal of Cell Communication and Signaling

, Volume 13, Issue 3, pp 279–280 | Cite as

FGFR2-mediated phosphorylation of PTEN at tyrosine 240 contributes to the radioresistance of glioma

  • Yuanliang Yan
  • Zhi Li
  • Shuangshuang Zeng
  • Xiang Wang
  • Zhicheng Gong
  • Zhijie XuEmail author
Bits and Bytes


Ionizing radiation (IR) is a standard-of-care treatment for glioma patients; however, the clinical efficacy is limited due to therapeutic resistance. A recent study published by Ma et al. (Cancer Cell 35:504–518, 2019) reported that the phosphorylation of phosphatase and tensin homolog (PTEN) at tyrosine 240 (pY240-PTEN) promotes the radioresistance of human glioma cells. After treatment with IR, the fibroblast growth factor receptor 2 (FGFR2)-mediated phosphorylation that generated pY240-PTEN could effectively promote the decondensation of chromatin through an interaction with Ki-67, leading to DNA damage repair and radioresistance. However, such promising findings need to be addressed in detail after considering the following points. (1) The authors should take into consideration whether or not the nuclear-cytoplasmic translocalization of PTEN occurs. (2) The roles of FGFR2-PTEN downregulation should be validated using both genetic and pharmacological inhibition models. (3) Some of the data shown by the authors are confusing and did not support the conclusion that patients with higher PTEN and FGFR2 expression were relatively IR resistant.


FGFR2 pY240-PTEN Radioresistance Glioma 



This work is supported by National Natural Science Foundation of China (No. 81803035, 81703036, 81572946), and China Postdoctoral Science Foundation (No. 2017 M610510).

Author contributions

Conception and design: ZC Gong, YL Yan, and ZJ Xu. Writing, review, and/or revision of the manuscript: YL Yan, Z Li, and ZJ Xu. Administrative, technical, or material support: Z Li, SS Zeng and X Wang.

Compliance with ethical standards

Conflict of interest

The authors declare no conflicts of interest.


  1. Chua V, Orloff M, Teh JL, Sugase T, Liao C, Purwin TJ, Lam BQ, Terai M, Ambrosini G, Carvajal RD, Schwartz G, Sato T, Aplin AE (2019) Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma. EMBO Mol Med 11.
  2. Elosegui-Artola A, Andreu I, Beedle AEM, Lezamiz A, Uroz M, Kosmalska AJ, Oria R, Kechagia JZ, Rico-Lastres P, Le Roux AL, Shanahan CM, Trepat X, Navajas D, Garcia-Manyes S, Roca-Cusachs P (2017) Force triggers YAP nuclear entry by regulating transport across nuclear pores. Cell 171:1397–1410 e1314. CrossRefGoogle Scholar
  3. Huang T, Kim CK, Alvarez AA, Pangeni RP, Wan X, Song X, Shi T, Yang Y, Sastry N, Horbinski CM, Lu S, Stupp R, Kessler JA, Nishikawa R, Nakano I, Sulman EP, Lu X, James CD, Yin XM, Hu B, Cheng SY (2017) MST4 phosphorylation of ATG4B regulates autophagic activity, tumorigenicity, and radioresistance in glioblastoma. Cancer Cell 32:840–855 e848. CrossRefGoogle Scholar
  4. Kosugi S, Hasebe M, Tomita M, Yanagawa H (2009) Systematic identification of cell cycle-dependent yeast nucleocytoplasmic shuttling proteins by prediction of composite motifs. Proc Natl Acad Sci U S A 106:10171–10176. CrossRefGoogle Scholar
  5. Ma J, Benitez JA, Li J, Miki S, Ponte de Albuquerque C, Galatro T, Orellana L, Zanca C, Reed R, Boyer A, Koga T, Varki NM, Fenton TR, Nagahashi Marie SK, Lindahl E, Gahman TC, Shiau AK, Zhou H, DeGroot J, Sulman EP, Cavenee WK, Kolodner RD, Chen CC, Furnari FB (2019) Inhibition of nuclear PTEN tyrosine phosphorylation enhances glioma radiation sensitivity through attenuated DNA repair. Cancer Cell 35:504–518 e507. CrossRefGoogle Scholar
  6. Shen SM, Ji Y, Zhang C, Dong SS, Yang S, Xiong Z, Ge MK, Yu Y, Xia L, Guo M, Cheng JK, Liu JL, Yu JX, Chen GQ (2018) Nuclear PTEN safeguards pre-mRNA splicing to link Golgi apparatus for its tumor suppressive role. Nat Commun 9:2392. CrossRefGoogle Scholar

Copyright information

© The International CCN Society 2019

Authors and Affiliations

  1. 1.Department of Pharmacy, Xiangya HospitalCentral South UniversityChangshaChina
  2. 2.National Clinical Research Center for Geriatric Disorders, Xiangya HospitalCentral South UniversityChangshaChina
  3. 3.Center for Molecular Medicine, Xiangya Hospital, Key Laboratory of Molecular Radiation Oncology of Hunan ProvinceCentral South UniversityChangshaChina
  4. 4.Department of Pathology, Xiangya HospitalCentral South UniversityChangshaChina

Personalised recommendations